Given the significant influence seen with p53 mutations, ICC set forth a separate entity whenever TP53 mutations are present, defined as AML with mutation TP53 when a somatic TP53 mutation is present with a variant allele frequency of >10%. The gene discussed is TP53; the disease is intrahepatic cholangiocarcinoma.